- Home
- Updates in HCM Management: An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023
Updates in HCM Management: An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023
- Guidelines
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
In this programme 'Updates in HCM Management: An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023', Prof Elena Arbelo (University of Barcelona, ES) and Prof Juan Pablo Kaski (University College London, UK), offer comprehensive insights into the updated guidelines. They delve into the latest developments in hypertrophic cardiomyopathy (HCM), provide treatment recommendations for obstructive hypertrophic cardiomyopathy (oHCM), and discuss how these new guidelines impact the current approach to managing these conditions.
This course is tailored to assist healthcare practitioners in comprehending the most recent guideline recommendations and ensuring their effective implementation. The authors explore how medical practices can adapt to incorporate new therapeutic agents for oHCM and clarify the responsibilities associated with prescribing these therapies.
Support Statement
This programme is supported through an educational grant from Bristol Myers Squibb.
Disclosure
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Updates in HCM Management: An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Downloadable Infographics
Target Audience
- Cardiologists
- Heart Failure Specialists
- Electrophysiologists
- Cardiac Surgeons
- HCPs who specialise in treating HCM
Learning Objectives
Upon completion of this activity, participants will be able to:
- Recall guideline updates relevant to the use of disease modifying agents in hypertrophic cardiomyopathy
- Identify patients who, according to guidelines, may benefit from emerging disease modifying therapies prior to septal ablation therapy or being managed by symptom control alone
- Discuss long-term management strategies for patients receiving myosin inhibitor therapy
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Session 1 | What’s New for HCM? | 9m 6s | Elena Arbelo Juan-Pablo Kaski |
| Session 2 | Practical Implications for Practitioners | 17m 59s | Elena Arbelo Juan-Pablo Kaski |
| Session 3 | Q&A and Discussion | 29m 46s | Elena Arbelo Juan-Pablo Kaski |
Speaker
Related Courses
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity